Lisa Vermunt (@LisaVermunt) header
Lisa Vermunt (@LisaVermunt) profile picture

@AlzheimerAms | MD | PhD | biofluid biomarkers | autosomal dominant Alzheimer | proteomics | disease modelling | clinical trials

Amsterdam, Nederland
Joined May 2014
Photo by Lisa Vermunt (@LisaVermunt)Photo by Lisa Vermunt (@LisaVermunt)Photo by Lisa Vermunt (@LisaVermunt)Photo by Lisa Vermunt (@LisaVermunt)Photo by Lisa Vermunt (@LisaVermunt)Photo by Lisa Vermunt (@LisaVermunt)Photo by Lisa Vermunt (@LisaVermunt)Photo by Lisa Vermunt (@LisaVermunt)Photo by Lisa Vermunt (@LisaVermunt)Photo by Lisa Vermunt (@LisaVermunt)
🙏Equally excited to share plasma glial fibrillary acidic protein (#GFAP) in #DIAN! 👉 see: bit.ly/3Gbg103 @alzdemjournals 👉 or go for the summary below by my dear co-author @PratishthaChat7 @AlzheimerAms @Alz_onderzoek @AmsNeuroscience #stichtingdioraphte
(1/6) Excited that our paper on plasma glial fibrillary acidic protein (#GFAP) in dominantly inherited #AlzheimersDisease is now out👉 doi.org/10.1002/alz.12879. @alzdemjournals. 🙏Many thanks @LisaVermunt @BrianGordon81 @RalphNMartins1 @CharlotteTeuni1 and all collaborators!
4
11
2,074
The dream of #biomarker #discovery with #proteomics - check out our preprint with our novel, replicable, mechanistically logical protein biomarkers in #CSF for #DLB medrxiv.org/content/10.1101/… @AlzheimerAms @AmsNeuroscience @BarcelonaBeta Del Campo,@CharlotteTeuni1 and others
6
439
Lisa Vermunt retweeted
The dream of #biomarker #discovery with #proteomics - check out our preprint with our novel, replicable, mechanistically logical protein biomarkers in #CSF for #DLB medrxiv.org/content/10.1101/… @AlzheimerAms @AmsNeuroscience @BarcelonaBeta Del Campo,@CharlotteTeuni1 and others
2
1
4
863
NWO vroeg aan 5 wetenschappers welke oproep zij aan de #politiek doen op #Prinsjesdag. Onderzoeker @LisaVermunt van @AlzheimerAms wil overbrengen hoe belangrijk kennis is. “Zonder wetenschap geen nieuwe medicijnen.” Lees alle oproepen: nwo.nl/prinsjesdag @NWONieuws
1
2
229
Very grateful for my #Veni grant! A boost for our research line on familial #AD. By tracing #astrocyte failure with #laboratory tests, we will better understand how #Alzheimer evolves, to further precise forecasting and faster treatments. @ZonMw @AlzheimerAms @AmsNeuroscience
NWO has awarded Veni funding of up to EUR 280,000 to 188 promising researchers from the full breadth of science. This will allow the laureates to further develop their own research ideas over the next three years. nwo.nl/en/news/veni-grant-fo…
6
1
1
19
1,739
Lisa Vermunt retweeted
A trio of studies make a strong case that SORL1 is the fourth familial Alzheimer’s gene. @AarhusUni @amsterdamumc ow.ly/tCRK50Pg2RZ
1
2
1
16
2,894
The dream of #biomarker #discovery with #proteomics - check out our preprint with our novel, replicable, mechanistically logical protein biomarkers in #CSF for #DLB medrxiv.org/content/10.1101/… @AlzheimerAms @AmsNeuroscience @BarcelonaBeta Del Campo,@CharlotteTeuni1 and others
2
1
4
863
Excited to share my newest senior author work in @Brain1878 !!!: CSF #proteomics in autosomal dominant #Alzheimer’s disease highlights parallels with sporadic disease academic.oup.com/brain/artic… @AlzheimerAms @GeneticAMS @AmsNeuroscience @CharlotteTeuni1 @OlinkProteomics
3
3
23
2,102
This CSF proteomics study demonstrates substantial biochemical similarities between ADAD and sporadic AD, suggesting involvement of the same biological processes. We identified several relatively novel proteins, which have potential as novel biomarkers.
1
1
99
With shared pathophysiological CSF changes, ADAD study findings might be translatable to sporadic AD, which could greatly expedite therapy development.
1
76
Lisa Vermunt retweeted
Breaking news: @EliLillyandCo Phase 3 trial of Donanemab is positive, showing significant slowing on cognitive and functional outcomes. Now we have two positive trials showing effects of amyloid clearance in Alzheimer's disease-- hugely exciting times! investor.lilly.com/news-rele…
39
4
102
11,093
Lisa Vermunt retweeted
Van Engelen et al. report that the use of urine as a matrix for neurofilament light chain (NfL) analysis to differentiate frontotemporal dementia from psychiatric disorders is not suitable and that urine NfL levels did not correlate with serum levels. bit.ly/40qNxYf
4
12
4,152
#TNFRSF4 and #TGF ββ-1 emerged as the top markers, being lower in fast-progressing patients compared to slow-progressing patients. None of our top markers stood out as strong individual predictors of subsequent #cognitive #decline.
1
100
Biological enrichment for cell signalling and immune response pathways, with lower levels in fast progressing patients. Taken together, we present a novel progression biomarker identification framework and protein leads for prediction of cognitive decline in dementia.
125